ABSTRACT
Background REM sleep behaviour disorder (RBD) is a disabling, often overlooked sleep disorder affecting up to 70% of patients with Parkinson’s disease. Identifying and treating RBD is critical to prevent severe sleep-related injuries, both to patients and bedpartners. Current diagnosis relies on nocturnal video-polysomnography, which is an expensive and cumbersome exam requiring specific clinical expertise.
Objectives To design, optimise, and validate a novel home-screening tool, termed RBDAct, that automatically identifies RBD in Parkinson’s patients based on wrist actigraphy only.
Methods Twenty-six Parkinson’s patients underwent two-week home wrist actigraphy worn on their more affected arm, followed by two non-consecutive in-lab evaluations. Patients were classified as RBD versus non-RBD based on dream enactment history and video-polysomnography. We characterised patients’ movement patterns during sleep using raw tri-axial accelerometer signals from wrist actigraphy. Machine learning classification algorithms were then trained to discriminate between patients with or without RBD using actigraphic features that described patients’ movements. Classification performance was quantified with respect to clinical diagnosis, separately for in-lab and at-home recordings.
Results Classification performance from in-lab actigraphic data reached an accuracy of 92.9±8.16% (sensitivity 94.9±7.4%, specificity 92.7±13.8%). When tested on home recordings, accuracy rose to 100% over the two-week window. Features showed robustness across tests and conditions.
Conclusions RBDAct provides reliable predictions of RBD in Parkinson’s patients based on home wrist actigraphy only. These results open new perspectives for faster, cheaper and more regular screening of sleep disorders, both for routine clinical practice and for clinical trials.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The RBDAct study stemmed from the Sleep, Awake & Move project (NSI.LS15.3), that was supported by the Advisory Board of EOC for Scientific Research (ABREOC) and the Swiss Parkinson's Association. EMM was funded by the Swiss National Science Foundation (Ambizione fellowship PZ00P3_180018).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of the Canton of Ticino, Switzerland, gave ethical approval for this work(Ref. 2016-00056).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data are available with a granted proposal upon reasonable request.
